We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis. These isolates included rough and mucoid Pseudomonas aeruginosa, Pseudomonas cepacia, Staphylococcus aureus, Haemophilus influenzae, and Escherichia coli. Selected isolates were tested by the broth microdilution method to examine the influence of various pHs, inoculum sizes, and biological fluids (serum or sputum from patients with cystic fibrosis). Fleroxacin MICs for 50 and 90% of isolates of P. aeruginosa were 2.0 and 4 ,ug/ml, those for P. cepacia were 2 and 16 ,ug/ml, those for S. aureus were 0.5 and 1 ,ug/ml, those for H. influenzae were 0.06 and 0.06 ,ug/ml, and those for E. coli were 0.01 and 0.03 ,ug/ml, respectively.
Fleroxacin, , is a newly developed synthetic trifluorinated quinolone with antimicrobial activity against a variety of pathogens, including mycobacteria, mycoplasmas, chlamydiae, and legionellae (24) . Like the other quinolones, its mechanism of action involves the inhibition of supercoiling activity of DNA gyrase (1, 7, 18, 29) . Data from preliminary investigations (26, 27) include an encouraging pharmacokinetic profile with excellent concentrations in serum and tissue and a very prolonged elimination half-life. Concentrations in serum may be two to three times those found with similar quinolone agents.
Based on these preliminary data, the current study was designed to examine the in vitro activity of fleroxacin against isolates from sputum from patients with cystic fibrosis (CF) pulmonary infections. These infections are often characterized by the emergence of multiply resistant strains following prolonged and repeated courses of antimicrobial therapy. In addition to inhibitory activity, representative isolates were tested for the influence of pH, inoculum size, and biological fluids on fleroxacin activity.
MATERIALS AND METHODS
Antibiotics. Fleroxacin powder was supplied by Hoffmann-La Roche, Inc., Nutley, N.J. Reagent-grade antimicrobial agents were obtained from their respective manufacturers. All antimicrobial agents were initially dissolved in appropriate solvents, as recommended by the manufacturers, and then diluted to a stock concentration of 2,560 ,ug/ml. All working antimicrobial solutions were stored at -70°C and used within 4 weeks of preparation.
Bacteria. A total of 200 bacterial isolates from the sputa of patients with CF consisting of Pseudomonas aeruginosa (n = 106), Pseudomonas cepacia (n = 14), Haemophilus influ-* Corresponding author. enzae (n = 26), Escherichia coli (n = 24), and Staphylococcus aureus (n = 30) were tested. These organisms were obtained from 27 CF centers in the United States that were participating in a multicenter study sponsored by the National Institutes of Health. Prior to use, all frozen isolates were thawed and subcultured at least twice onto appropriate solid medium. Pseudomonas species were subcultured onto mucoid maintenance agar (10) , and working stock cultures were stored on mucoid maintenance agar slants at room temperature. H on September 28, 2017 by guest http://aac.asm.org/ Downloaded from described previously (25) . By using a 50% sputum concentration as a diluent, various antimicrobial agent test panels were prepared, and subsequent MICs were determined with selected isolates of each test organism. Similarly, susceptibility determinations of selected bacterial isolates were made by using 50% concentrations of pooled human sera from patients with CF.
For studies involving bacterial inocula, the microdilution plates containing a concentration gradient of fleroxacin were seeded with test organisms to yield final inocula of 104, 105, 106, and 107 CFU/ml. Similarly, two isolates of each test species were exposed to fleroxacin that was adjusted to pHs 5, 6, 7, and 8. Following incubation at 37°C for 18 to 20 h, the MICs were determined.
Kill kinetic studies. By using various concentrations of fleroxacin, killing kinetics and regrowth patterns of P. aeruginosa (mucoid and nonmucoid) were investigated. Exponentially growing cultures (one mucoid and one nonmucoid isolate), each at a final inoculum of approximately 6 x 106 CFU/ml, were exposed to fleroxacin at concentrations ranging from 0.5 (one-half the MIC) to 8 (eight times the MIC) ,ug/ml. Following incubation (without agitation) (20) , bacterial numbers were measured at 0, 2, 4, 6, and 24 h. At these fixed time intervals, 0.1 ml (8) of the samples was removed from the tubes and 10-fold serial dilutions were made in sterile physiological saline. The same volume was subcultured onto Mueller-Hinton agar plates for standard colony count determinations. To ensure that any residual fleroxacin was diluted to insignificant concentrations prior to bacterial quantitation, 1-ml amounts were transferred to MuellerHinton agar containing an inoculum of the test organism and were shown to possess undetectable antibacterial activity. During this study, organisms which were not exposed to fleroxacin were processed as controls.
PAE. Using an arbitrarily selected isolate ofP. aeruginosa in the logarithmic growth phase and an inoculum of 106 CFU/ml, a determination of the postantibiotic effect (PAE) of fleroxacin was made. Following an initial incubation of the organism with fleroxacin for 2 h, the antimicrobial agent was removed by diluting the solution to 102 with fresh MuellerHinton broth. Regrowth was quantitated at time zero, before and after dilution, and hourly thereafter for 8 h by serial 10-fold dilutions in physiological saline and subcultured onto solid medium. During these experiments, a culture of the same isolate that was prepared as described above but that was not exposed to fleroxacin served as a control. All culture tubes were incubated at 37°C in a shaking water bath (5, 20) .
RESULTS
The antibacterial spectra and the various comparative quinolones and other antimicrobial agents evaluated in this study are depicted in Table 1 . Against P. aeruginosa, fleroxacin activity was similar to those of enoxacin and ofloxacin; however, ciprofloxacin was generally eightfold more active than the other quinolones, including fleroxacin.
Of 21 isolates of P. aeruginosa that were aminoglycoside, ceftazidime, and imipenem resistant, 86% were inhibited by fleroxacin at a concentration of 1 ,ug/ml or less, and 95% were inhibited by fleroxacin at 4 jig/ml or less, with no apparent differences between these and the more susceptible strains.
Fleroxacin inhibited 90% of S. aureus isolates at a concentration of 1 ,ug/ml; for H. influenzae the concentration was 0.063 jig/ml, and for E. coli the concentration was 0.03 ,ug/ml. In general, S. aureus was twofold more susceptible to fleroxacin than it was to norfloxacin and enoxacin, but it was twofold less susceptible to fleroxacin than it was to ciprofloxacin, ofloxacin, and nafcillin. In the other antimicrobial agent-organism combinations, fleroxacin activity paralleled those of the other quinolones, with the exception of ciprofloxacin, which had greater activity against both E. coli (MIC for 90% of strains tested, s0.008 ,ug/ml) and H. influenzae
(MIC for 90% of strains tested, 0.016 ,ug/ml). Effects of various growth conditions on fleroxacin activity. With the exception of occasional shifts, antibacterial activity against specific genera was not significantly influenced by changes in medium pH (Table 2) .
Although there were occasional twofold increases in MICs (for P. cepacia, H. influenzae, and S. aureus) at an inoculum density of 107 CFU/ml and occasional increases in the activity of fleroxacin at an inoculum density of 104 CFU/ml, variation of inoculum density did not have a significant effect on the activity of this drug within the range of inocula tested.
The susceptibilities of the organisms remained the same regardless of the inclusion of serum or sputum as a diluent.
Kill kinetic studies. For mucoid and nonmucoid isolates of P. aeruginosa, there was a 1-log-unit decrease in CFU following exposure to fleroxacin for 4 h at a concentration equal to or less than two times the MIC. At these concentrations, however, regrowth occurred during 24 h of incubation. At drug concentrations of eight times the MIC, there was a 3-log-unit decline for the mucoid strain and a 4-log-unit decrease for the nonmucoid strain after 4 h of incubation ( Fig. 1 and 2 ). At this drug concentration, there was no regrowth at 24 h for the mucoid strain and the nonmucoid P.
aeruginosa strain was present at a level 2 log1o units less than the level at the beginning of incubation. PAE. The results of bacterial quantitation as log1o CFU per milliliter was plotted against time. The PAE was calculated (5, 17) as follows: PAE (time) = T -C, where T is the time required for the count of CFU in the test culture to increase by 1 log unit above the count observed immediately after drug removal (by dilution), and C is the time required for the count of CFU in an untreated control culture to increase by 1 log10 unit following the same procedure. The PAE of fleroxacin for P. aeruginosa at a concentration of 2.5 p,g/ml (five times the MIC) was 2.25 h (Fig. 3) . DISCUSSION Progressive bronchopulmonary colonization and subsequent infection with a variety of pathogens that predominantly include P. aeruginosa (mucoid and nonmucoid strains) but that also feature P. cepacia, S. aureus, E. coli, and H. influenzae is the major cause of morbidity and mortality in patients with CF. Difficulties in eradicating these pathogens and the frequent emergence of resistance with prolonged and repeated courses of antimicrobial therapy have necessitated a continuous search for effective antimicrobial agents. Unfortunately, the newer antimicrobial agents have not provided a complete solution to this problem. Treatment failures from quinolones caused by the selection of resistant mutants of P. aeruginosa have been reported by some investigators (2, 3, 11, 23) . Other investigators (19) have also demonstrated low-level quinolone resistance involving S. aureus in patients without CF.
In this study, fleroxacin was one-to eightfold less active than ciprofloxacin but had activity equivalent to those of most of the other tested quinolones against mucoid and nonmucoid P. aeruginosa, P. cepacia, and E. coli strains. Clinically relevant fleroxacin activity against H. influenzae and S. aureus was often better than those of standard semisynthetic penicillins and cephalosporins. Even though the bacterial isolates used in the present study were derived from patients with CF, the antipseudomonal activity of fleroxacin was consistent with those found by other investigators (4, 6, 16) who used isolates from patients who did not have CF. In general, the various quinolone agents have shown consistent activities against isolates from patients with CF (14, 15) .
The in vitro activity of this antimicrobial agent suggests that pulmonary infections caused by P. aeruginosa with or without other pathogens characteristically found in patients with CF may be amenable to oral fleroxacin therapy. In view of the need for repeated treatment regimens in patients with CF, the potential ability of this drug to eradicate mucoid P.
aeruginosa is particularly appealing.
The inhibitory activity of fleroxacin against most of the pathogens that we tested was encouraging. There was little or no inoculum effect, and activity was not significantly affected by changes in medium pH. These observations have also been reported by other investigators (12, 28) . Additionally, there was no diminution of activity by serum or sputum from patients with CF consistent with the low degree of protein binding (27%) exhibited by fleroxacin when ultrafiltration techniques are used (16) .
Our experiments confirmed a PAE of 2.25 h for fleroxacin, consistent with the PAE calculated for ciprofloxacin (9) and various quinolones (22) . The marked PAE observed for various quinolone agents (even under conditions in which their activities are normally diminished) may have clinical implications. A prolonged PAE may allow fleroxacin levels in serum and tissue to fall below the bactericidal level for considerable time intervals without permitting bacterial regrowth and loss of drug efficacy.
Fleroxacin is characterized by a broad range of activity, oral bioavailability, encouraging pharmacokinetic profiles, including an elimination half-life of 10 to 12 h, low serumbinding affinity, high concentrations in tissue and plasma, and excellent pulmonary diffusion and retention (U. Loos, F. Sorgel, G. Marklein, F. Vogel, and E. Hubner, Proc. 16th Int. Congr. Chemother., p. 229, 1989). These features could be useful in the treatment of infections in patients with CF. Although additional in vivo studies are needed to confirm the relevance of these findings, further assessment of the potential utility of fleroxacin in CF bronchopulmonary infections in patients with CF is indicated. 
